As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock. The details of this cooperative arrangement are available in the 8-K filed by the Company this morning, which can be found on NW Bio’s website at www.nwbio.com Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both and Europe.